Fairvalue-Calculator Fairvalue-Calculator
EN DE

ADC Therapeutics SA (ADCT) Fair Value & Analysis

Healthcare · US · Market cap $141M

Price$1.09
Fair Value$1.60
Upside+46.8%
Quality95/100
Evidence: Low Range $1.20 – $2.00

Fair value as of: Jun 23, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

ADC Therapeutics SA (ADCT) currently trades at $1.09, while our model-based Fair Value estimate is $1.60 — implying the stock looks roughly 46.8% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Pha…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is ADC Therapeutics SA (ADCT) undervalued?
As of Jun 23, 2026, our model estimates a fair value of $1.60 versus a price of $1.09 — about +47% (undervalued). Model-based estimate, not financial advice.
What is the fair value of ADCT?
Our 21-model fair value for ADC Therapeutics SA is $1.60 (as of Jun 23, 2026), built from audited fundamentals. The current price is $1.09.
What is the quality score of ADCT?
ADC Therapeutics SA has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.